Shares of Generation Bio Co. (GBIO) are rising more than 25% Thursday morning after the company announced collaboration with Moderna, Inc. (MRNA) to develop non-viral genetic medicines.
As per the agreement, Generation Bio will receive an upfront payment of $40 million in cash, and a $36 million equity investment at a premium over recent share prices, the company said. Generation Bio is also eligible for milestone payments and royalties.
"This collaboration represents a foundational investment in our platform science, both deepening our pipeline of rare and prevalent liver disease programs beyond hemophilia A and accelerating our work to reach outside of the liver with nucleic acid therapies," Commented Phillip Samayoa, Chief Strategy Officer of Generation Bio.
GBIO is at $4.87 currently. It has traded in the range of $3.40-$9.59 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.